lba: results of revive - rusfertide in patients with polycythemia vera
Published 1 year ago • 567 plays • Length 5:40Download video MP4
Download video MP3
Similar videos
-
2:05
results from the phase i sal-relax trial: venetoclax plus cytarabine and mitoxantrone in r/r aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:42
results of phase i/ii study of epcoritamab r-dhax/c in patients with r/r dlbcl eligible for autosct
-
1:21
ruxolitinib plus venetoclax in heavily pretreated patients with r/r aml
-
1:51
results for trial of lcl161 for pmf, post-pv mf, and post-et mf patients
-
1:46
results for the follow-up of the response study
-
2:58
lba: sierra results - iomab-b prior to allogeneic transplantation vs conventional care in r/r aml
-
1:43
gilteritinib monotherapy vs combination therapy in r/r flt3-mutated aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:52
cytoreductive therapy for patients with pv
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
-
6:44
the current landscape for the treatment of r/r aml in the post-transplant setting
-
1:06
feasibility of treatment with bispecifics in patients with myeloma with prior bcma exposure
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
4:04
lba: phase iii study of iomab-b prior to allogeneic transplantation vs conventional care in r/r aml
-
3:23
updated safety and efficacy results of abbv-383, a novel bsab, in patients with r/r multiple myeloma
-
1:24
final phase 2 results of lcl161 for myelofibrosis
-
4:45
safety and efficacy of obe-cel in r/r adult b-all: results of the pivotal felix study
-
1:24
triple-negative myelofibrosis: disease features and outcomes